# EDGAR Filing Document

**Accession Number:** 0001900304
**File Stem:** 0001654954-25-008668
**Filing Date:** 2025-7
**Character Count:** 6312
**Document Hash:** beae02c5b901d164296a6edc178866f8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-008668.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001654954-25-008668

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haleon plc
- **CENTRAL INDEX KEY:** 0001900304
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41411
- **FILM NUMBER:** 251169112

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY
- **BUSINESS PHONE:** 44 1932 822000

**MAIL ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DRVW 2022 Ltd
- **DATE OF NAME CHANGE:** 20211217

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **FORM 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2025

 **Commission File Number: 001-41411**

 **Haleon plc**

(Translation of registrant's name into English)

 **Building 5, First Floor, The Heights,**

 **Weybridge, Surrey, KT13 0NY**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 **EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | 31 July 2025 - "Haleon 2025 Half Year Results" |
| [99.2](h125releasevf.pdf) | 31 July 2025 - "[Haleon 2025 Half Year Results](h125releasevf.pdf)" |

---

99.1<br>

![](a2714t000.jpg)

 **Haleon plc: 2025 Half Year Results**

 **31 July 2025:** Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its half year results statement for the year ending 31 December 2025 is available at <u>http://www.rns-pdf.londonstockexchange.com/rns/2714T_1-2025-7-30.pdf</u>.

The half year results statement will also be available on the Haleon website <u>www.haleon.com/investors</u>, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at <u>https://data.fca.org.uk/#/nsm/nationalstoragemechanism</u>.

 **Dividend**

Consistent with our policy to pay approximately one third of the prior year full year dividend as the interim dividend the Board has declared a H1 2025 interim dividend of 2.2 pence per ordinary share, up 10% on the interim dividend in 2024. This interim dividend is expected to be paid on 18 September 2025 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 15 August 2025 (the record date). The ex-dividend date is expected to be 14 August 2025 for ordinary shareholders and 15 August 2025 for holders of ADS. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline for the DRIP is 1 September 2025. The DRIP is provided by Equiniti Financial Services Limited, more information is available at <u>www.shareview.co.uk/info/drip</u>.

Subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.

 **Presentation for analysts and shareholders**

A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7:00am BST (8:00 am CEST) on 31 July 2025 and can be accessed at <u>www.haleon.com/investors</u>. This will be followed by a Q&A session at 9:30am BST (10:30am CEST).

For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:

---

| | |
|:---|:---|
| UK: | +44 (0) 808 189 0158 |
| US: | +1 855 979 6654 |
| All other: | +44 (0) 203 936 2999 |
| Passcode: | 656863 |

---

An archived webcast of the presentation will be available later on the day of the results and can be accessed at <u>www.haleon.com/investors</u><u>.</u>

This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.

Amanda Mellor

Company Secretary

 **Enquiries**

---

| | | | |
|:---|:---|:---|:---|
| <br> **Investors** | <br> **Investors** | <br> **Media** | <br> **Media** |
| Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| <br> Email: investor-relations@haleon.com | <br> Email: investor-relations@haleon.com | <br> Email: corporate.media@haleon.com | <br> Email: corporate.media@haleon.com |

---

 **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu* and *Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information please visit <u>www.haleon.com</u>.

 **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **HALEON PLC**<br> *(Registrant)* | **HALEON PLC**<br> *(Registrant)* |
| Date: July 31, 2025 | By: | /s/ Amanda Mellor | /s/ Amanda Mellor |
|  |  | Name: | Amanda Mellor |
|  |  | Title: | Company Secretary |

---

### Attached PDF Documents

**Attachment 1:** `h125releasevf.pdf`

_No text found in this document._